p ddr1  (Cell Signaling Technology Inc)

Journal: Cancer Cell International

Article Title: PHI-501, a dual inhibitor of RAF and DDR1/2, overcomes MAPK drug resistance in Melanoma

doi: 10.1186/s12935-026-04271-w

Figure Lengend Snippet: MAPK inhibitor-resistant melanoma cells exhibit enhanced DDR1/2 signaling. ( A ) Clonogenic assay showing the validation of drug-resistant cell lines. ( B ) Quantification of clonogenic assay shown in Fig. 1A. Data are presented as relative colony formation (%) normalized to the control group and expressed as the mean ± SEM, n = 3 replicates. Statistical significance was determined by two-way ANOVA. * p < 0.05, # p < 0.001, † p < 0.001, ‡ p < 0.0001. ( C ) Cell viability assay of RAF and MEK inhibitors in parental cells and drug-resistant cells for 48 h. Data are presented as the mean ± SEM, n = 3 replicates. ( D ) Western blot analysis of pERK and pAKT signaling responses in parental and resistant melanoma cells following 48-h treatment with vehicle or the corresponding resistance-selecting drug(s) at 1 µM. ( E ) Bubble plot representing Gene Set Enrichment Analysis (GSEA) using hallmark gene set comparing parental and resistant melanoma cells. Pathway enrichment was calculated using GSEA, with color indicating NES (blue = downregulated, red = upregulated) and bubble size representing −log10(p-value). ( F ) SK-MEL-2 and SK-MEL-2BR cells were stimulated with type I collagen (40 µg/ml) for 18 h to activate DDR signaling

Article Snippet: The membranes were incubated overnight at 4 °C with primary antibodies diluted in 5% BSA in TBST as indicated in the text: p-DDR1 (Cell Signaling Technology, CST14531 ), p-DDR1/2 (R&D Systems, MAB25382), p-AKT (Cell Signaling Technology, CST4058), AKT (Cell Signaling Technology, CST9272), p-MEK (Cell Signaling Technology, CST9121), p-ERK (Cell Signaling Technology, CST9101), ERK (Cell Signaling Technology, CST9102), Cyclin D1(Cell Signaling Technology, CST2978), and Survivin (Cell Signaling Technology, CST2808).

Techniques: Clonogenic Assay, Biomarker Discovery, Control, Viability Assay, Western Blot

Journal: Cancer Cell International

Article Title: PHI-501, a dual inhibitor of RAF and DDR1/2, overcomes MAPK drug resistance in Melanoma

doi: 10.1186/s12935-026-04271-w

Figure Lengend Snippet: DDR1 and DDR2 are associated with MAPK pathway activation and therapeutic resistance in melanoma. ( A ) Kaplan–Meier survival analysis showing patient outcomes based on DDR1 and DDR2 expression levels across all TCGA cancer types. Patients were stratified into high (top 25%) and low (bottom 25%) expression groups, and overall survival (OS) was analyzed. ( B ) Proteomic analysis of BRAF/NRAS-mutant SKCM. Box plots demonstrate differential expression of AKT and phosphorylated MEK1 (pMEK1-S217/S221) between wild-type and mutant groups. ( C ) Correlation heatmaps between DDR1/2 and key genes in the MAPK and AKT signaling pathways in TCGA-SKCM samples. Color intensity represents the correlation value, with red indicating a positive correlation. Significance levels are indicated by asterisks (* p < 0.05, ** p < 0.01, *** p < 0.001). ( D ) Correlation analysis revealing DDR1 expression (DepMap) and MAPK pathway inhibitor sensitivity (GDSC2) in melanoma cell lines. Scatter plots depicting correlations between DDR1 expression levels and IC50 to Dabrafenib (left) and Trametinib (right)

Article Snippet: The membranes were incubated overnight at 4 °C with primary antibodies diluted in 5% BSA in TBST as indicated in the text: p-DDR1 (Cell Signaling Technology, CST14531 ), p-DDR1/2 (R&D Systems, MAB25382), p-AKT (Cell Signaling Technology, CST4058), AKT (Cell Signaling Technology, CST9272), p-MEK (Cell Signaling Technology, CST9121), p-ERK (Cell Signaling Technology, CST9101), ERK (Cell Signaling Technology, CST9102), Cyclin D1(Cell Signaling Technology, CST2978), and Survivin (Cell Signaling Technology, CST2808).

Techniques: Activation Assay, Expressing, Mutagenesis, Quantitative Proteomics, Protein-Protein interactions

Journal: Frontiers in Immunology

Article Title: DDR1 as a key prognostic biomarker in non-small cell lung cancer: identification, validation, and potential therapeutic implications

doi: 10.3389/fimmu.2025.1690829

Figure Lengend Snippet: Differential expression of DDR1 and survival analysis in the TCGA dataset. (A) Differential expression of DDR1 between tumor and control samples. (B) Differential expression of DDR1 between different age groups. (C) Differential expression of DDR1 between different sex groups. (D) Differential expression of DDR1 across different pathological stages. (E) Differential expression of DDR1 across different T stages. (F) Differential expression of DDR1 across different N stages. (G) Differential expression of DDR1 across different M stages. (H) Survival analysis results.

Article Snippet: Patient tissue samples were cut into 4-μm-thick sections, deparaffinized, and rehydrated before being treated with antigen retrieval solution (10 mmol/L sodium citrate buffer, pH 6.0) and then reacted with anti-DDR1 antibodies (1:3200; Cell Signaling Technology).

Techniques: Quantitative Proteomics, Control

Journal: Frontiers in Immunology

Article Title: DDR1 as a key prognostic biomarker in non-small cell lung cancer: identification, validation, and potential therapeutic implications

doi: 10.3389/fimmu.2025.1690829

Figure Lengend Snippet: Construction of a nomogram for NSCLC patients based on DDR1 expression from the TCGA database. (A) Univariate Cox analysis. (B) Multivariate Cox analysis. (C) Nomogram for clinical features. (D) Calibration curves for 1-, 3-, and 5-year outcomes. (E) Decision curve analysis (DCA) for the nomogram model.

Article Snippet: Patient tissue samples were cut into 4-μm-thick sections, deparaffinized, and rehydrated before being treated with antigen retrieval solution (10 mmol/L sodium citrate buffer, pH 6.0) and then reacted with anti-DDR1 antibodies (1:3200; Cell Signaling Technology).

Techniques: Expressing

Journal: Frontiers in Immunology

Article Title: DDR1 as a key prognostic biomarker in non-small cell lung cancer: identification, validation, and potential therapeutic implications

doi: 10.3389/fimmu.2025.1690829

Figure Lengend Snippet: Somatic mutation analysis between the high and low DDR1 expression groups. (A) Correlation analysis between DDR1 expression and the DNA methylation level. (B) DDR1 expression differences between the DDR1-mutant and wild-type groups. (C) Survival analysis between the DDR1-mutant and wild-type groups. (D) Distribution of TMB between the high and low DDR1 expression groups. (E) Waterfall plot showing common somatic gene mutations, with a bar chart on the right indicating the mutation frequency in each group.

Article Snippet: Patient tissue samples were cut into 4-μm-thick sections, deparaffinized, and rehydrated before being treated with antigen retrieval solution (10 mmol/L sodium citrate buffer, pH 6.0) and then reacted with anti-DDR1 antibodies (1:3200; Cell Signaling Technology).

Techniques: Mutagenesis, Expressing, DNA Methylation Assay

Journal: Frontiers in Immunology

Article Title: DDR1 as a key prognostic biomarker in non-small cell lung cancer: identification, validation, and potential therapeutic implications

doi: 10.3389/fimmu.2025.1690829

Figure Lengend Snippet: Immune infiltration analysis. (A) Correlations between immune cell infiltration and DDR1 expression evaluated by four algorithms. (B) Correlations between the expression levels of DDR1 and those of seven types of immunoregulatory genes.

Article Snippet: Patient tissue samples were cut into 4-μm-thick sections, deparaffinized, and rehydrated before being treated with antigen retrieval solution (10 mmol/L sodium citrate buffer, pH 6.0) and then reacted with anti-DDR1 antibodies (1:3200; Cell Signaling Technology).

Techniques: Expressing

Journal: Frontiers in Immunology

Article Title: DDR1 as a key prognostic biomarker in non-small cell lung cancer: identification, validation, and potential therapeutic implications

doi: 10.3389/fimmu.2025.1690829

Figure Lengend Snippet: Drug sensitivity analysis. Differences in the IC50 values for methotrexate (A) , vinblastine (B) , doxorubicin (C) , cisplatin (D) , docetaxel (E) , and gefitinib (F) between the high and low DDR1 expression groups.

Article Snippet: Patient tissue samples were cut into 4-μm-thick sections, deparaffinized, and rehydrated before being treated with antigen retrieval solution (10 mmol/L sodium citrate buffer, pH 6.0) and then reacted with anti-DDR1 antibodies (1:3200; Cell Signaling Technology).

Techniques: Expressing

Journal: Frontiers in Immunology

Article Title: DDR1 as a key prognostic biomarker in non-small cell lung cancer: identification, validation, and potential therapeutic implications

doi: 10.3389/fimmu.2025.1690829

Figure Lengend Snippet: Correlation analysis of immune therapy predictors. Distribution of TLS (A) , TIDE (B) and CYT (C) scores between the high and low DDR1 expression groups. (D) Differences in tumor immune cycle steps between the high and low DDR1 expression groups. (E) Correlations between immune checkpoint genes and DDR1 expression.

Article Snippet: Patient tissue samples were cut into 4-μm-thick sections, deparaffinized, and rehydrated before being treated with antigen retrieval solution (10 mmol/L sodium citrate buffer, pH 6.0) and then reacted with anti-DDR1 antibodies (1:3200; Cell Signaling Technology).

Techniques: Expressing

Journal: Frontiers in Immunology

Article Title: DDR1 as a key prognostic biomarker in non-small cell lung cancer: identification, validation, and potential therapeutic implications

doi: 10.3389/fimmu.2025.1690829

Figure Lengend Snippet: Pseudotime analysis. (A) Differentiation trajectory of 13 cell subpopulations in tumor samples (colors represent different cell subtypes). (B) Developmental timeline of 13 cell subpopulations (color intensity from dark to light represents pseudotime). (C) Timeline showing changes in DDR1 expression during the developmental trajectory. (D) UMAP plot showing DDR1 expression across different cell types.

Article Snippet: Patient tissue samples were cut into 4-μm-thick sections, deparaffinized, and rehydrated before being treated with antigen retrieval solution (10 mmol/L sodium citrate buffer, pH 6.0) and then reacted with anti-DDR1 antibodies (1:3200; Cell Signaling Technology).

Techniques: Expressing

Journal: Frontiers in Immunology

Article Title: DDR1 as a key prognostic biomarker in non-small cell lung cancer: identification, validation, and potential therapeutic implications

doi: 10.3389/fimmu.2025.1690829

Figure Lengend Snippet: Enrichment analysis between the high and low DDR1 expression groups. (A) Volcano plot of the differential expression analysis results (red: upregulated; blue: downregulated). (B–G) Enrichment analysis results for KEGG analysis, BP analysis, CC analysis, MF analysis, GSVA, and GSEA.

Article Snippet: Patient tissue samples were cut into 4-μm-thick sections, deparaffinized, and rehydrated before being treated with antigen retrieval solution (10 mmol/L sodium citrate buffer, pH 6.0) and then reacted with anti-DDR1 antibodies (1:3200; Cell Signaling Technology).

Techniques: Expressing, Quantitative Proteomics

Journal: Frontiers in Immunology

Article Title: DDR1 as a key prognostic biomarker in non-small cell lung cancer: identification, validation, and potential therapeutic implications

doi: 10.3389/fimmu.2025.1690829

Figure Lengend Snippet: Effect of DDR1 knockdown on the proliferation, invasion, migration, and adhesion of CALU3 and NCI-H292 cells. A cell viability assay (A) , apoptosis analysis by flow cytometry (B) , and a colony formation assay (C) demonstrated changes in cell proliferation following DDR1-siRNA transfection. Scratch assays (D) revealed that DDR1 knockdown significantly reduced the migration ability of CALU3 and NCI-H292 cells. Transwell assays (E, F) revealed a marked decrease in the number of cells that crossed the Transwell membrane, indicating a significant reduction in migration and invasion capacity. Furthermore, an adhesion assay (G) demonstrated that DDR1 knockdown led to a substantial decrease in the adhesion of CALU3 and NCI-H292 cells to the extracellular matrix. ***P<0.001, **P<0.01, *P<0.05. NC, negative control; si, small interfering; OD, optical density.

Article Snippet: Patient tissue samples were cut into 4-μm-thick sections, deparaffinized, and rehydrated before being treated with antigen retrieval solution (10 mmol/L sodium citrate buffer, pH 6.0) and then reacted with anti-DDR1 antibodies (1:3200; Cell Signaling Technology).

Techniques: Knockdown, Migration, Viability Assay, Flow Cytometry, Colony Assay, Transfection, Membrane, Cell Adhesion Assay, Negative Control

Journal: Frontiers in Immunology

Article Title: DDR1 as a key prognostic biomarker in non-small cell lung cancer: identification, validation, and potential therapeutic implications

doi: 10.3389/fimmu.2025.1690829

Figure Lengend Snippet: DDR1 expression in NSCLC tumor tissue. (A) Representative IHC images of DDR1 expression in NSCLC tissues. -: negative staining, +: mild positive staining, ++: moderate positive staining, +++: strong positive staining. Magnification, up 20×; down 80×. (B) Comparison of the IHC scores of DDR1 in NSCLC tumor tissues and paired adjacent normal tissues**** P < 0.0001. (C) Comparison between LUSC and LUAD. ** P < 0.01.

Article Snippet: Patient tissue samples were cut into 4-μm-thick sections, deparaffinized, and rehydrated before being treated with antigen retrieval solution (10 mmol/L sodium citrate buffer, pH 6.0) and then reacted with anti-DDR1 antibodies (1:3200; Cell Signaling Technology).

Techniques: Expressing, Negative Staining, Staining, Comparison